ATE483455T1 - Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen - Google Patents

Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE483455T1
ATE483455T1 AT05754106T AT05754106T ATE483455T1 AT E483455 T1 ATE483455 T1 AT E483455T1 AT 05754106 T AT05754106 T AT 05754106T AT 05754106 T AT05754106 T AT 05754106T AT E483455 T1 ATE483455 T1 AT E483455T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions containing
mixed crystals
mixed
crystal
Prior art date
Application number
AT05754106T
Other languages
English (en)
Inventor
Matthew Peterson
Mark Oliveira
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE483455T1 publication Critical patent/ATE483455T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT05754106T 2004-05-28 2005-05-27 Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen ATE483455T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57524704P 2004-05-28 2004-05-28
PCT/US2005/018636 WO2005117585A1 (en) 2004-05-28 2005-05-27 Mixed co-crystals and pharmaceutical compositions comprising the same

Publications (1)

Publication Number Publication Date
ATE483455T1 true ATE483455T1 (de) 2010-10-15

Family

ID=35462668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05754106T ATE483455T1 (de) 2004-05-28 2005-05-27 Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen

Country Status (6)

Country Link
US (1) US7671093B2 (de)
EP (1) EP1755388B1 (de)
JP (1) JP2008501024A (de)
AT (1) ATE483455T1 (de)
DE (1) DE602005023986D1 (de)
WO (1) WO2005117585A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070564A2 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Methods of treating obesity using enterostatin
WO2007070563A2 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Stable solid forms of enterostatin
JP2009542813A (ja) * 2006-07-11 2009-12-03 ハルクネスス プハルマセウティカルス,インコーポレイテッド 飽食因子を使用して肥満を治療する方法
US20080091026A1 (en) * 2006-10-11 2008-04-17 Transform Pharmaceuticals, Inc. Novel crystal of n-[[(5s)-3-[4-(2,6-dihydro-2-methylpyrrolo[3,4-c]pyrazol-5(4h)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
GB0702402D0 (en) 2007-02-08 2007-03-21 Thar Pharmaceuticals Inc Method of creating crystalline substances
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ.ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
DE102007030695A1 (de) * 2007-07-01 2009-01-08 Sciconcept Gmbh Co-Kristalle aus Harnstoff mit Amid- und/oder Harnstoffderivaten
KR20100075960A (ko) * 2007-10-29 2010-07-05 디에스엠 아이피 어셋츠 비.브이. 레스베라트롤 및 펙틴을 함유하는 조성물
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
US8513236B2 (en) 2010-02-03 2013-08-20 Laurus Labs Private Limited Pterostilbene cocrystals
GB201411802D0 (en) * 2014-07-02 2014-08-13 Univ Bradford Effervescent compositions
CN110354081A (zh) * 2019-08-01 2019-10-22 聊城高新生物技术有限公司 可减少在水介质中析出的利托那韦固体分散体的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5366738A (en) 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20060052432A1 (en) * 2002-09-20 2006-03-09 Julius Remenar Pharmaceutical compositions with improved dissolution
ATE550022T1 (de) * 2003-02-28 2012-04-15 Mcneil Ppc Inc Pharmazeutische mischkristalle von celecoxib- nicotinamid
KR101184797B1 (ko) * 2003-09-04 2012-09-20 세파론, 인코포레이티드 모다피닐 조성물
AR046410A1 (es) * 2003-09-18 2005-12-07 Cephalon Inc Composiciones farmaceuticas para la liberacion modificada de modafinilo

Also Published As

Publication number Publication date
US7671093B2 (en) 2010-03-02
DE602005023986D1 (de) 2010-11-18
US20050267209A1 (en) 2005-12-01
JP2008501024A (ja) 2008-01-17
EP1755388B1 (de) 2010-10-06
EP1755388A4 (de) 2009-09-16
EP1755388A1 (de) 2007-02-28
WO2005117585A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
SV2006002174A (es) Composicion de anticuerpo her2
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EP1755388A4 (de) Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
UY30748A1 (es) Compuesto0s novedosos
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0515594A (pt) inibidores da interação entre mdm2 e p53
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
NO20065726L (no) Forbindelser og sammensetninger for avlevering av aktive forbindelser.
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
SE0401762D0 (sv) Novel compounds
AR109263A2 (es) Composición que comprende moxidectina
ATE375810T1 (de) Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
NO20062739L (no) Kontrollert frigivining av topirimat i flytende doseringsform
ATE400272T1 (de) Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer
CL2025002072A1 (es) Inhibidores de prmt5–mta.
BRPI0512986A (pt) novos derivados de hidantoìna
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren
AR040287A1 (es) Plataforma para formulaciones transdermicas (pft)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties